Evotec and Dow AgroSciences are collaborating in an effort to support compounds in development at the latter firm.

Under the terms of the research agreement, Dow will leverage Evotec’s chemical proteomics services. Evotec will be performing quantitative chemical proteomics services to clear up Dow’s phenotypic screening results. Financial terms were not disclosed.

“We look forward to working with Dow AgroSciences on this project,” Evotec COO Mario Polywka, Ph.D., said in a statement. “This collaboration highlights the broad applicability of Evotec’s industry leading chemical proteomics platform to determine cellular target affinities and mechanisms of action on a proteome wide level and in a native context.”

Added Dow’s William Kleschick, Ph.D., discovery global leader: “This collaboration enhances [our] technology toolbox to accelerate our efforts to deliver novel solutions to our customers around the world.”

Previous articleSorrento Licenses Ben-Gurion University HCV Antibody Clones
Next articleAstraZeneca Launches Cancer Collaborations